Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.
about
Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy.HIV protease inhibitors: a review of molecular selectivity and toxicityHypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.A review of the aetiology of dyslipidaemia and hyperlipidaemia in patients with HIV.Practical discussion on switching studies and how this relates to managing lipids.The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent.A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.Investigational protease inhibitors as antiretroviral therapies.[HIV infection : chronic disease with comorbidities].Drug therapies for HIV-related metabolic disorders.A single centre cohort experience with a new once daily antiretroviral drug.Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes.Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.Severe HIV-associated hypertriglyceridaemia treated with rosuvastatin plus omega-3 fatty acids.Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients.Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.
P2860
Q25255216-9DDCC6BA-A2E2-4A0F-8737-433E30537A5BQ28082749-B5C4B013-FF22-4291-A272-1E7584617D6DQ35176441-8E13E6D2-48D3-4D44-9AFE-A96655DDC6D4Q35567828-13D5B017-09A6-4932-8DCA-5C97B0BD3F0AQ35963960-A4958338-BA26-46BF-89DA-A7B3DF34A363Q36292303-A4B44129-B888-4442-AB98-66047642376EQ36292308-0E5FE09D-DAC6-410E-BA1C-CAF70B919C05Q36441470-F6A595F0-3D5A-435B-A8CC-9DC76DD707CCQ36741508-0B1A6636-6F3E-4CD1-A256-368A85B00D57Q36974022-B21EEF1B-983F-46D0-9D4F-EFC349BB4C47Q37582521-321F1042-92AD-4552-B788-07A204855C13Q38413754-105F36D7-9215-4DD9-AC29-6FA85A11F8F0Q38837421-24CD98C4-5E45-4753-801A-94575669AC5CQ42107646-EC1C57EA-9D3C-4FE9-BB76-70E73EDF2FC5Q43244207-763ED1B5-55DA-41A1-B4D3-603007A56786Q44922052-86577081-3A61-4839-B962-EB10E456DB21Q45396970-7BDAFCDB-8DB0-495C-8098-51765A1231B9Q45922693-CB73C2EB-B621-4A53-8104-557C699A115BQ46127996-F697FA5A-FFC0-4A60-921A-29FB65C53F4DQ51625767-E1A866D2-4286-4921-BDAD-EF6B54FC14AB
P2860
Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Atazanavir--a once-daily HIV p ...... wo randomized clinical trials.
@ast
Atazanavir--a once-daily HIV p ...... wo randomized clinical trials.
@en
type
label
Atazanavir--a once-daily HIV p ...... wo randomized clinical trials.
@ast
Atazanavir--a once-daily HIV p ...... wo randomized clinical trials.
@en
prefLabel
Atazanavir--a once-daily HIV p ...... wo randomized clinical trials.
@ast
Atazanavir--a once-daily HIV p ...... wo randomized clinical trials.
@en
P2093
P2860
P1476
Atazanavir--a once-daily HIV p ...... wo randomized clinical trials.
@en
P2093
Alexandra Thiry
Ian A Sanne
José M Gatell
Kathleen Squires
Linda Odeshoo
Lisa D Percival
Michael D Giordano
Pedro E Cahn
Peter J Piliero
Sarah Shelton
P2860
P356
10.1177/154510970400300304
P577
2004-07-01T00:00:00Z